X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (9519) 9519
Magazine Article (28) 28
Dissertation (3) 3
Book Chapter (2) 2
Web Resource (2) 2
Book / eBook (1) 1
Newsletter (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (6869) 6869
thiazoles - therapeutic use (5482) 5482
male (3657) 3657
animals (3551) 3551
female (3118) 3118
thiazoles - pharmacology (2479) 2479
pharmacology & pharmacy (1787) 1787
middle aged (1775) 1775
adult (1653) 1653
thiazoles - adverse effects (1438) 1438
mice (1390) 1390
thiazoles - administration & dosage (1279) 1279
aged (1230) 1230
rats (1206) 1206
treatment outcome (1041) 1041
thiazoles (1029) 1029
piperazines - therapeutic use (969) 969
dose-response relationship, drug (944) 944
dasatinib (887) 887
oncology (880) 880
thiazolidinediones (845) 845
thiazoles - chemistry (755) 755
cell line, tumor (728) 728
hypoglycemic agents - therapeutic use (718) 718
pyrimidines - therapeutic use (715) 715
tetrazolium salts (676) 676
antipsychotic agents - therapeutic use (645) 645
analysis (624) 624
antineoplastic agents - therapeutic use (620) 620
psychiatry (615) 615
time factors (609) 609
neurosciences (595) 595
double-blind method (575) 575
cancer (573) 573
apoptosis (558) 558
thiazoles - pharmacokinetics (541) 541
administration, oral (540) 540
diabetes mellitus, type 2 - drug therapy (538) 538
hematology (529) 529
adolescent (527) 527
expression (521) 521
biochemistry & molecular biology (520) 520
chemistry, medicinal (510) 510
in-vitro (508) 508
research (506) 506
drug therapy (504) 504
protein kinase inhibitors - therapeutic use (491) 491
care and treatment (488) 488
double-blind (483) 483
imatinib mesylate (468) 468
drug therapy, combination (467) 467
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (446) 446
efficacy (430) 430
thiazines - therapeutic use (426) 426
disease models, animal (421) 421
clinical neurology (415) 415
cell survival - drug effects (413) 413
pyridines - therapeutic use (406) 406
therapy (404) 404
clinical trials as topic (402) 402
apoptosis - drug effects (400) 400
thiazoles - metabolism (396) 396
antineoplastic agents - pharmacology (390) 390
piperazines - adverse effects (389) 389
schizophrenia - drug therapy (386) 386
meloxicam (384) 384
schizophrenia (382) 382
cells, cultured (375) 375
medicine, general & internal (375) 375
rats, sprague-dawley (372) 372
aged, 80 and over (358) 358
medicine & public health (356) 356
research article (353) 353
health aspects (352) 352
antipsychotic agents - adverse effects (351) 351
benzamides (349) 349
benzothiazoles (341) 341
proteins (340) 340
chromans - therapeutic use (339) 339
endocrinology & metabolism (337) 337
cell proliferation - drug effects (333) 333
activation (330) 330
anti-inflammatory agents, non-steroidal - therapeutic use (328) 328
insulin resistance (328) 328
pyrimidines - pharmacology (326) 326
pharmacology/toxicology (320) 320
cell biology (319) 319
troglitazone (319) 319
structure-activity relationship (317) 317
young adult (314) 314
multidisciplinary sciences (313) 313
inhibition (305) 305
cell line (304) 304
pharmacokinetics (302) 302
ziprasidone (299) 299
child (298) 298
medicine (298) 298
cells (296) 296
risk factors (294) 294
safety (291) 291
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (8911) 8911
Japanese (199) 199
German (175) 175
French (122) 122
Russian (83) 83
Italian (73) 73
Spanish (62) 62
Portuguese (43) 43
Chinese (31) 31
Polish (22) 22
Hungarian (11) 11
Danish (8) 8
Czech (7) 7
Swedish (6) 6
Norwegian (5) 5
Finnish (4) 4
Hebrew (4) 4
Romanian (4) 4
Dutch (3) 3
Ukrainian (3) 3
Croatian (2) 2
Slovak (2) 2
Arabic (1) 1
Bulgarian (1) 1
Korean (1) 1
Lithuanian (1) 1
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Thrombosis and Haemostasis, ISSN 0340-6245, 09/2015, Volume 113, Issue 5, pp. 931 - 942
Summary Several new anticoagulants have entered the clinical arena or are under clinical development. These drugs include indirect (fondaparinux) and direct... 
Review Article | Rivaroxaban | Antidotes | Dabigatran | New anticoagulants | Apixaban | ANDEXANET-ALPHA | VITAMIN-K ANTAGONISTS | rivaroxaban | apixaban | ATRIAL-FIBRILLATION | antidotes | IN-VITRO | ANTIIDIOTYPIC ANTIBODIES | PROTHROMBIN COMPLEX CONCENTRATE | ORAL ANTICOAGULANTS | MOLECULAR-WEIGHT HEPARIN | dabigatran | PERIPHERAL VASCULAR DISEASE | HEALTHY-VOLUNTEERS | HEMATOLOGY | ACUTE VENOUS THROMBOEMBOLISM | Recombinant Proteins - therapeutic use | Pyrazoles - therapeutic use | Anticoagulants - administration & dosage | Thrombosis - complications | Humans | Antibodies, Monoclonal - therapeutic use | Heparin - therapeutic use | Hemorrhage - prevention & control | Thiazoles - therapeutic use | Dabigatran - therapeutic use | Vitamin K - antagonists & inhibitors | Benzamides - therapeutic use | Anticoagulants - chemistry | Factor Xa - therapeutic use | Intracranial Hemorrhages - prevention & control | Rivaroxaban - therapeutic use | Pyridines - therapeutic use | Polysaccharides - therapeutic use | Hemostatics - chemistry | Antibodies, Monoclonal, Humanized - therapeutic use | Administration, Oral | Antithrombins - therapeutic use | Infusions, Parenteral | Clinical Trials as Topic | Factor Xa Inhibitors - therapeutic use | Animals | Protamines - therapeutic use | Pyridones - therapeutic use | Thrombosis - drug therapy | Hemorrhage - chemically induced | Hemostatics - therapeutic use
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 2011, Volume 2013, Issue 1, p. CD006626
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 2010, Volume 2013, Issue 5, p. CD006654
Journal Article
Circulation (New York, N.Y.), ISSN 0009-7322, 07/2016, Volume 134, Issue 3, pp. 248 - 261
Vitamin K antagonists are commonly used by clinicians to provide anticoagulation to patients who have or are at risk of having thrombotic events. In addition... 
anticoagulants | atrial fibrillation | venous thromboembolism | hemorrhage | CARDIAC & CARDIOVASCULAR SYSTEMS | ACTIVATED FACTOR-VII | ATRIAL-FIBRILLATION | IN-VITRO | THROMBIN GENERATION | DABIGATRAN ETEXILATE | PROTHROMBIN COMPLEX CONCENTRATE | SYMPTOMATIC VENOUS THROMBOEMBOLISM | PRACTICAL MANAGEMENT | PERIPHERAL VASCULAR DISEASE | STAGE RENAL-DISEASE | FACTOR XA INHIBITOR | Recombinant Proteins - therapeutic use | Plasma | Dabigatran - adverse effects | Pyrazoles - therapeutic use | Humans | Hemorrhage - prevention & control | Recombinant Proteins - adverse effects | Thiazoles - therapeutic use | Factor VIIa - therapeutic use | Arginine - analogs & derivatives | Dabigatran - therapeutic use | Thiazoles - adverse effects | Pyridines - adverse effects | Rivaroxaban - adverse effects | Factor Xa - therapeutic use | Rivaroxaban - therapeutic use | Factor Xa - adverse effects | Pyrazoles - adverse effects | Pyridines - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Administration, Oral | Antithrombins - therapeutic use | Piperazines - therapeutic use | Dabigatran - antagonists & inhibitors | Piperazines - adverse effects | Factor Xa Inhibitors - therapeutic use | Hemorrhage - drug therapy | Antithrombins - adverse effects | Factor Xa Inhibitors - adverse effects | Blood Coagulation Factors - therapeutic use | Arginine - adverse effects | Pyridones - therapeutic use | Hemorrhage - chemically induced | Hemostatics - therapeutic use | Arginine - therapeutic use | Pyridones - adverse effects
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 03/2017, Volume 2017, Issue 3, p. CD006324
Background Between 40% and 70% of people with treatment‐resistant schizophrenia do not respond to clozapine, despite adequate blood levels. For these people, a... 
Drugs | Clinical care ‐ by specific additional problem | Anti‐psychotics | Mental health | Amisulpride | Schizophrenia | Haloperidol | Aripiprazole | Sulpiride | Schizophrenia & psychosis | Antipsychotic Agents | Thiazoles | Drug Therapy, Combination | Risperidone | Weight Gain | Drug Resistance | Clinical care ‐ by treatment category | Piperazines | Quetiapine Fumarate | Clozapine | Randomized Controlled Trials as Topic | Dibenzothiazepines | Treatment resistant | General | Antipsychotic medication: atypical | Medicine General & Introductory Medical Sciences | Risperidone [therapeutic use] | REFRACTORY SCHIZOPHRENIA | EFFICACY | Humans | STATISTICS NOTES | Male | RISPERIDONE | MEDICINE, GENERAL & INTERNAL | Schizophrenia [drug therapy] | Thiazoles [therapeutic use] | Female | Clozapine [adverse effects; therapeutic use] | Sulpiride [analogs & derivatives; therapeutic use] | Dibenzothiazepines [therapeutic use] | Antipsychotic Agents [adverse effects; therapeutic use] | AUGMENTATION | DrugTherapy, Combination | NETWORK METAANALYSIS | ARIPIPRAZOLE-CLOZAPINE | SUBOPTIMAL RESPONSE | DOUBLE-BLIND | RATING-SCALE | Piperazines [therapeutic use] | Clozapine - therapeutic use | Antipsychotic Agents - adverse effects | Thiazoles - therapeutic use | Aripiprazole - adverse effects | Sulpiride - analogs & derivatives | Dibenzothiazepines - therapeutic use | Risperidone - therapeutic use | Antipsychotic Agents - therapeutic use | Aripiprazole - therapeutic use | Adult | Sulpiride - adverse effects | Sulpiride - therapeutic use | Haloperidol - therapeutic use | Piperazines - therapeutic use | Haloperidol - adverse effects | Schizophrenia - drug therapy | Clozapine - adverse effects
Journal Article
Journal Article